- Isracann Biosciences (IPOT) has signed a distribution agreement for Praesidio Health products with Pure Integrative Pharmacy
- Pure works to bridge the gap between conventional and complementary medicine and become an integrative and accessible hub of health for their clients
- Praesidio is developing natural health products (NHPs) using an evidence-based process
- Isracann engages in the cultivation, manufacturing, distribution, and branding of medical cannabis-based products
- Isracann Biosciences Inc. (IPOT) is up 12.50 per cent, trading at C$0.045 per share at 11:33 am ET
Isracann Biosciences (IPOT) has signed a distribution agreement for Praesidio Health products with Pure Integrative Pharmacy.
Pure Integrative Pharmacy includes 17 locations in British Columbia. Pure works to bridge the gap between conventional and complementary medicine. It aims to become an integrative and accessible health hub for its clients.
Pure focuses on evidence-based efficacy and safety. It strives to bring the best of conventional and complementary medicine to empower customers to take control of their health.
Phil Floucault, CEO of Isracann, commented on the news.
“The Praesidio team has been working hard to bring our NPN formulations forward and get them into the hands of consumers. Pure Integrative Pharmacy, with their commitment to evidence-based complementary medicines and cutting-edge products, is a perfect fit for Praesidio Health products. This is the first step in delivering on our commitment to our shareholders of having products at market in Q4 2022. We are very excited to be working with the team at Pure. We view this contract as the catalyst for expanding our distribution network not only in Canada, but throughout North America.”
Praesidio is developing natural health products (NHPs) using an evidence-based process. Pioneering NHPs and therapeutics, Praesidio is actively developing several NHP candidates for utility in a range of conditions. It includes post-viral exposure prophylaxis, urological, anxiety/stress, immune boosting, and sleep aids.
Praesidio has submitted all first round product formulations to Health Canada for review and approval as natural health products.
Isracann engages in the cultivation, manufacturing, distribution, and branding of medical cannabis-based products.
Isracann Biosciences Inc. (IPOT) is up 12.50 per cent, trading at C$0.045 per share at 11:33 am ET.